Experience with Tofacitinib in Patients with Ulcerative Colitis: Data from a United States Claims Database
Background Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Aims To evaluate real-world data in US patients with UC receiving tofacitinib. Methods Characteristics and outcomes of patients with UC initiating tofacitinib between 2018 and 2019 were assessed using data from the IBM® MarketScan® claims database. The index date was the first tofacitinib claim; pre- and post-index periods were 12 months. Outcomes included tofacitinib adherence/persistence, oral corticosteroid (OCS) use, and healthcare resource utilization (HCRU) and costs. Results Of 276 patients with UC who initiated tofacitinib, 68 (24.6%) were bio-naïve, and 208 (75.4%) bio-experienced. At month 12, overall median tofacitinib adherence (proportion of days covered) was 0.82 (mean 0.68); 43.8% of patients discontinued tofacitinib (90-day gap). Of patients receiving OCS during the post-index 16-week tapering period, 40.4% discontinued OCS up to 12 months post-index. OCS use decreased in patients continuing tofacitinib versus those discontinuing tofacitinib (29.7% vs 59.5%, respectively). Reductions in all-cause and UC-related outpatient visits were observed for bio-naïve (− 1.34 and − 0.88, respectively) and bio-experienced (− 4.72 and − 5.16, respectively) patients, post-index. Decreased UC-related costs per year were observed for bio-experienced patients (difference in post-index vs pre-index, − US$12,448; driven by changes in pharmacy costs), but not for bio-naïve patients (US$47,152). Conclusions In this real-world analysis in a mostly bio-experienced population, the majority of US patients with UC initiating tofacitinib remained on therapy at 12 months, and OCS use was reduced with tofacitinib treatment. HCRU (all patients) and UC-related costs were reduced in bio-experienced patients. Graphical Abstract The majority of patients with ulcerative colitis starting tofacitinib in this real-world study continued therapy at 12 months; there was a reduction in the use of steroids, and a decrease in healthcare resournce utilization and costs..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:68 |
|---|---|
| Enthalten in: |
Digestive diseases and sciences - 68(2023), 10 vom: 28. Aug., Seite 3985-3993 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chiorean, Michael [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Healthcare resource utilization |
|---|
| Anmerkungen: |
© The Author(s) 2023 |
|---|
| doi: |
10.1007/s10620-023-08063-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR053162579 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR053162579 | ||
| 003 | DE-627 | ||
| 005 | 20231002143950.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231002s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10620-023-08063-4 |2 doi | |
| 035 | |a (DE-627)SPR053162579 | ||
| 035 | |a (SPR)s10620-023-08063-4-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chiorean, Michael |e verfasserin |0 (orcid)0000-0002-4238-9988 |4 aut | |
| 245 | 1 | 0 | |a Experience with Tofacitinib in Patients with Ulcerative Colitis: Data from a United States Claims Database |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a Background Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Aims To evaluate real-world data in US patients with UC receiving tofacitinib. Methods Characteristics and outcomes of patients with UC initiating tofacitinib between 2018 and 2019 were assessed using data from the IBM® MarketScan® claims database. The index date was the first tofacitinib claim; pre- and post-index periods were 12 months. Outcomes included tofacitinib adherence/persistence, oral corticosteroid (OCS) use, and healthcare resource utilization (HCRU) and costs. Results Of 276 patients with UC who initiated tofacitinib, 68 (24.6%) were bio-naïve, and 208 (75.4%) bio-experienced. At month 12, overall median tofacitinib adherence (proportion of days covered) was 0.82 (mean 0.68); 43.8% of patients discontinued tofacitinib (90-day gap). Of patients receiving OCS during the post-index 16-week tapering period, 40.4% discontinued OCS up to 12 months post-index. OCS use decreased in patients continuing tofacitinib versus those discontinuing tofacitinib (29.7% vs 59.5%, respectively). Reductions in all-cause and UC-related outpatient visits were observed for bio-naïve (− 1.34 and − 0.88, respectively) and bio-experienced (− 4.72 and − 5.16, respectively) patients, post-index. Decreased UC-related costs per year were observed for bio-experienced patients (difference in post-index vs pre-index, − US$12,448; driven by changes in pharmacy costs), but not for bio-naïve patients (US$47,152). Conclusions In this real-world analysis in a mostly bio-experienced population, the majority of US patients with UC initiating tofacitinib remained on therapy at 12 months, and OCS use was reduced with tofacitinib treatment. HCRU (all patients) and UC-related costs were reduced in bio-experienced patients. Graphical Abstract The majority of patients with ulcerative colitis starting tofacitinib in this real-world study continued therapy at 12 months; there was a reduction in the use of steroids, and a decrease in healthcare resournce utilization and costs. | ||
| 650 | 4 | |a Real-world data |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Tofacitinib |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Ulcerative colitis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Oral corticosteroids |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Healthcare resource utilization |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Ha, Christina |4 aut | |
| 700 | 1 | |a Hur, Peter |4 aut | |
| 700 | 1 | |a Sharma, Puza P. |4 aut | |
| 700 | 1 | |a Gruben, David |4 aut | |
| 700 | 1 | |a Khan, Nabeel H. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Digestive diseases and sciences |d Dordrecht : Springer Science + Business Media B.V., 1934 |g 68(2023), 10 vom: 28. Aug., Seite 3985-3993 |w (DE-627)SPR011830255 |w (DE-600)2015102-0 |x 1573-2568 |7 nnns |
| 773 | 1 | 8 | |g volume:68 |g year:2023 |g number:10 |g day:28 |g month:08 |g pages:3985-3993 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10620-023-08063-4 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 68 |j 2023 |e 10 |b 28 |c 08 |h 3985-3993 | ||